代谢组学
吉非替尼
化学
药物作用
药品
细胞
作用机理
癌细胞
药理学
抗药性
行动方式
谷胱甘肽
计算生物学
癌症研究
癌症
生物化学
生物
内科学
医学
体外
受体
酶
遗传学
表皮生长因子受体
色谱法
作者
Guizhen Zhu,Wenmei Zhang,Yaoyao Zhao,Tian Chen,Hanyu Yuan,Yuanxing Liu,Guangsheng Guo,Zhihong Liu,Xiayan Wang
标识
DOI:10.1021/acs.analchem.2c05351
摘要
Studying the mechanisms of drug antitumor activity at the single-cell level can provide information about the responses of cell subpopulations to drug therapy, which is essential for the accurate treatment of cancer. Due to the small size of single cells and the low contents of metabolites, metabolomics-based approaches to studying the mechanisms of drug action at the single-cell level are lacking. Herein, we develop a label-free platform for studying the mechanisms of drug action based on single-cell metabolomics (sMDA-scM) by integrating intact living-cell electro-launching ionization mass spectrometry (ILCEI-MS) with metabolomics analysis. Using this platform, we reveal that non-small-cell lung cancer (NSCLC) cells treated by gefitinib can be clustered into two cell subpopulations with different metabolic responses. The glutathione metabolic pathway of the subpopulation containing 14.4% of the cells is not significantly affected by gefitinib, exhibiting certain resistance characteristics. The presence of these cells masked the judgment of whether cysteine and methionine metabolic pathway was remarkably influenced in the analysis of overall average results, revealing the heterogeneity of the response of single NSCLC cells to gefitinib treatment. The findings provide a basis for evaluating the early therapeutic effects of clinical medicines and insights for overcoming drug resistance in NSCLC subpopulations.
科研通智能强力驱动
Strongly Powered by AbleSci AI